Venous thromboembolism (VTE) is the formation of blood clots inside the blood vessel. These clots restrict blood flow through the circulatory system. It is classified into two type’s deep vein thrombosis and pulmonary embolism. Formation of blood clot in a deep vein (generally in the leg) is called deep vein thrombosis. The formed deep vein thrombosis clot break off and travels to the lungs, called as pulmonary embolism. Pulmonary embolism is a serious complication from deep vein thrombosis. It occurs in almost one-third of patients suffering from deep vein thrombosis. Venous thromboembolism can occur at any age; however, it is common in adults aged 60 and above. People who are overweight, older, whose blood is thicker than normal or suffer from some other diseases such as autoimmune disorders (rheumatoid arthritis, lupus, etc.) or cancer are at a higher risk of venous thromboembolism. Hospitalization due to major trauma (fractures or immobilization) or surgery increases the risk for venous thromboembolism. Up to 60% of venous thromboembolism cases occur during or after hospitalization. Venous thromboembolism equally affects men and women. Globally, venous thromboembolism is the third most common cardiovascular disease and leading cause of death and disability.
Venous thromboembolism is a life-threatening medical condition that requires immediate medical treatment. Treatment primarily focuses on breaking the clots and preventing further formation of clots. Treatment includes blood thinning agents such as anticoagulants (such as unfractionated and low molecular weight heparin as well as warfarin), mechanical devices (compression stockings), and thrombolytic therapy (tissue plasminogen activator). The venous thromboembolism market is expected to expand in the near future, led by the development of novel oral anticoagulants (NOACs) to overcome the limitation of current treatment options and provide improved patient of care. NOACs are classified into direct thrombin inhibitors (argatroban, dabigatran), which inhibit factor IIa (thrombin), and factor Xa inhibitors (rivaroxaban, edoxaban, apixaban). NOACs offer major pharmacological benefits over current vitamin K antagonists (heparin or warfarin). These include rapid onset and offset of action, predictable pharmacokinetics, and less drug interactions, which eliminate the need for regular coagulation monitoring associated with conventional anticoagulant therapy. Increase in government expenditure, rise in incidence rate of venous thromboembolism, growth in patient awareness about treatment, and high unmet needs of current treatment options are fueling the venous thromboembolism market. However, complex pathophysiology of the disease, high cost of treatment, and side effects associated with it act as key restraints for the venous thromboembolism market.
The venous thromboembolism market can be segmented based on disease type, product type, and geography. In terms of disease type, the venous thromboembolism market can be segregated into deep vein thrombosis and pulmonary embolism. The pulmonary embolism segment is estimated to expand more than the deep vein thrombosis segment, as pulmonary embolism is the third most common cause for hospital related deaths. Based on product type, the venous thromboembolism market can be divided into anticoagulants, medical devices, and others. In anticoagulant segment, NOAC’s market is expected to grow because it eliminates the need for regular coagulation monitoring, overcoming the major limitation of current standard of care.
In terms of geography, the venous thromboembolism market can be classified into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America dominates the venous thromboembolism market, followed by Europe, due to the higher incidence and prevalence rate than that in Asia Pacific and Middle East & Africa, increase in demand for advance treatment, and rise in geriatric population in the region. Asia Pacific is an emerging market for venous thromboembolism due to the developing healthcare infrastructure and rising government expenditure in the healthcare industry. However, affordability issues, lack of proper treatment, and poor patient education are factors restraining the venous thromboembolism market in such as Middle East & Africa and Latin America.
Major players operating in the venous thromboembolism market include Bristol-Myers Squibb Company, Sanofi S.A., Pfizer, Inc., Daiichi Sankyo Co. Ltd., Johnson & Johnson, AbbVie Inc., Merck & Co., and Astellas Pharma Inc.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.